Cybin Granted U.S. Patent In Support Of CYB003 Program In MDD
Express News | Cybin Announces Additional U.S. Patent Supporting Its Cyb003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
Cybin (CYBN) Gets a Buy From H.C. Wainwright
Cybin to Participate at the 28th Annual Milken Institute Global Conference
Cybin Announces Additional Strategic Partnership Agreements To Support PARADIGM, Multinational Phase 3 Program Evaluating CYB003
Express News | Cybin - Engages 18 Clinical Sites for Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Mdd
Express News | Cybin Inc - Second Phase 3 Study Embrace Expected to Begin Mid-2025
Express News | Reported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment
Cybin Entyers Strategic Partnership With Osmind To Help Bring Innovative Mental Health Treatments To Patients In Need
Express News | Trading Circulation Newsletter Mention Of CYBN
NYSE American Net Change Percentage Gainers & Losers
Sunrun, HubSpot, Rocket, Summit, Cybin: Trending by Analysts
Cybin Price Target Announced at $35.00/Share by Guggenheim
Guggenheim Initiates Cybin(CYBN.US) With Buy Rating, Announces Target Price $35
Express News | 'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment
Cybin Inc. Reports Q3 2025 Financial Results and Strategic Progress
Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025
A. G. P. Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Cybin (CYBN) and Corbus Pharmaceuticals (CRBP)
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet